Expression of Sclerostin scFv and the Effect of Sclerostin scFv on Healing of Osteoporotic Femur Fracture in Rats

Cell Biochemistry and Biophysics

Volumn 69, Issue 2, 2014, Pages 229-235

  Yao, Qi ^a   Ni, Jie ^a   Hou, Yu ^a   Ding, Lixiang ^a   Zhang, Licheng ^b   Jiang, Hua ^b  

^a CAPITAL MEDICAL UNIVERSITY   (China)

^b CHINESE PLA GENERAL HOSPITAL   (China)

Author keywords

Bone healing; Femur fracture; Osteoporosis; scFv; Sclerostin; SOST; SOST scFv; VH and VL gene

Indexed keywords

ALKALINE PHOSPHATASE; BONE MORPHOGENETIC PROTEIN; CALCIUM; GENETIC MARKER; OSTEOCALCIN; PHOSPHATE; RECOMBINANT PROTEIN; SINGLE CHAIN FRAGMENT VARIABLE ANTIBODY; SOST PROTEIN, RAT;

ANIMAL; BIOSYNTHESIS; BLOOD; BONE DEVELOPMENT; CELL DIFFERENTIATION; COMPUTER ASSISTED TOMOGRAPHY; CYTOLOGY; DISEASE MODEL; DRUG EFFECTS; FEMALE; FEMUR; GENETIC MARKER; GENETICS; HEK293 CELL LINE; HUMAN; MESENCHYMAL STROMA CELL; METABOLISM; OSTEOPOROTIC FRACTURES; PATHOLOGY; PHYSIOLOGY; RAT; SPRAGUE DAWLEY RAT;

ALKALINE PHOSPHATASE; ANIMALS; BONE MORPHOGENETIC PROTEINS; CALCIUM; CELL DIFFERENTIATION; DISEASE MODELS, ANIMAL; FEMALE; FEMUR; GENETIC MARKERS; HEK293 CELLS; HUMANS; MESENCHYMAL STROMAL CELLS; OSTEOCALCIN; OSTEOGENESIS; OSTEOPOROTIC FRACTURES; PHOSPHATES; RATS; RATS, SPRAGUE-DAWLEY; RECOMBINANT PROTEINS; SINGLE-CHAIN ANTIBODIES; TOMOGRAPHY, X-RAY COMPUTED;

EID: 84901228538     PISSN: 10859195     EISSN: None     Source Type: Journal    
DOI: 10.1007/s12013-013-9787-1     Document Type: Article

References (20)

1. Rachner, T. D., Khosla, S., & Hofbauer, L. C. (2011). Osteoporosis: Now and the future. Lancet, 377(9773), 1276-1287.
2. Lewiecki, E. M. (2011). Sclerostin: A novel target for intervention in the treatment of osteoporosis. Discovery Medicine, 12(65), 263.
3. Ominsky, M. S., et al. (2011). Inhibition of sclerostin by monoclonal antibody enhances bone healing and improves bone density and strength of nonfractured bones. Journal of Bone and Mineral Research, 26, 1012-1021.
4. Tian, X., et al. (2011). Sclerostin antibody increases bone mass by stimulating bone formation and inhibiting bone resorption in a hindlimb-immobilization rat model. Bone, 48(2), 197-201.
5. Li, X., et al. (2010). Inhibition of sclerostin by monoclonal antibody increases bone formation, bone mass, and bone strength in aged male rats. Journal of Bone and Mineral Research, 25(12), 2647-2656.
6. Tian, X., et al. (2010). Treatment with a sclerostin antibody increases cancellous bone formation and bone mass regardless of marrow composition in adult female rats. Bone, 47(3), 529-533.
7. Agholme, F., et al. (2010). Sclerostin antibody treatment enhances metaphyseal bone healing in rats. Journal of Bone and Mineral Research, 25(11), 2412-2418.
8. Ominsky, M. S., et al. (2010). Two doses of sclerostin antibody in cynomolgus monkeys increases bone formation, bone mineral density, and bone strength. Journal of Bone and Mineral Research, 25(5), 948-959.
9. Lewiecki, E. M. (2011). Sclerostin monoclonal antibody therapy with AMG 785: A potential treatment for osteoporosis. Expert Opinion on Biological Therapy, 11(1), 117-127.
10. Padhi, D., et al. (2011). Single-dose, placebo-controlled, randomized study of AMG 785, a sclerostin monoclonal antibody. Journal of Bone and Mineral Research, 26(1), 19-26.
11. Ahmad, Z. A., et al. (2012). scFv antibody: Principles and clinical application. Clinical and Developmental Immunology. Article ID 980250. doi: 10. 1155/2012/980250.
12. McCafferty, J., et al. (1990). Phage antibodies: Filamentous phage displaying antibody variable domains. Nature, 348, 552-554.
13. Kong, H. Y., Chen, Y. P., Yang, S. Q., et al. (2004). Experimental analysis of osteoporotic detection marker of ovariectomized rats. Chinese Journal of Orthopaedic Trauma, 17(4), 204-206.
14. Lane, N. E., & Silverman, S. L. (2010). Anabolic therapies. Current Osteoporosis Reports, 8(1), 23-27.
15. Sibai, T., et al. (2011). Anabolic agents and bone quality. Clinical Orthopaedics and Related Research, 469(8), 2215-2224.
16. Papapoulos, S. E. (2011). Targeting sclerostin as potential treatment of osteoporosis. Annals of the Rheumatic Diseases, 70(Suppl 1), i119-i122.
17. Moester, M., et al. (2010). Sclerostin: Current knowledge and future perspectives. Calcified Tissue International, 87(2), 99-107.
18. Geng, S., et al. (2006). Binding activity difference of anti-CD20 scFv-Fc fusion protein derived from variable domain exchange. Cellular and Molecular Immunology, 3(6), 439-443.
19. Luo, D., et al. (1995). VI-linker-VH orientation-dependent expression of single chain Fv containing an engineered disulfide-stabilized bond in the framework regions. Journal of Biochemistry, 118(4), 825-831.
20. Robert, B., et al. (1999). Tumor targeting with newly designed biparatopic antibodies directed against two different epitopes of the carcinoembryonic antigen (CEA). International Journal of Cancer, 81(2), 285-291.